CURRENT POSSIBILITIES OF ANTICOAGULANT THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION
https://doi.org/10.17650/1818-8338-2015-9-3-15-21
Abstract
Clinical medicine develops towards increasingly more specialization; however, there are diseases faced by physicians of different specialties. The most common cardiac arrhythmia after extrasystoles is atrial fibrillation (AF) that increases the risk of cardiac embolism, primarily ischemic stroke, by several times. Identification of the causes of stroke and systemic embolisms has given rise to the creation of clinical scales to assess the risk of their development. According to current guidelines, the longterm use of oral anticoagulants (for an indefinite time) is the best way to prevent cardiac embolic complications with medications in AF. This approach outperforms both monotherapy with acetyl-salicylic acid alone and in combination with clopidogrel. The administration of anticoagulants is warranted in patients having risk factors for stroke, no matter what the clinical type of AF (paroxysmal, constant, or persistent).
Until quite recently, oral anticoagulant therapy has implied the use of drugs from a group of vitamin K antagonists (VKAs), among which warfarin is at the forefront; however, the pharmacodynamic and pharmacokinetic features of the drug substantially complicate its practical application. The results of a number of large randomized controlled trials have shown that novel oral anticoagulants (NOACs) may be used along with VKAs in patients with nonvalvular AF (i. e. in the absence of mitral stenosis or mechanical cardiac valvular prostheses). As com pared with warfarin, NOACs have advantages: a much less interaction with foods and drugs and no need for continuous monitoring using coagulation tests and for drug dose adjustment (although the dose should be corrected in renal dysfunctions). When prescribing therapy with VKAs or NOACs, a risk for hemorrhagic complications should be defined. The patient should be informed of the advantages and disadvantages of each therapy option in order to take into account the real possibilities of safely maintaining the persistent coagulation level and the patients, choices. Prognosis and quality of life may be effectively influenced in an AF patient where physicians of all specialties understand each other well and know general approaches to treating these patents. A general practitioner plays a key role in the coordination of all actions.
About the Authors
M. Yu. Gilyarov
Regional Vascular Center, N.I. Pirogov City Clinical Hospital One, Moscow Healthcare Department; 8 Leninsky Prospect, Build. 8, Moscow, 115149, Russia;
Department of Emergency and Preventive Cardiology, I.M. Sechenov First Moscow State Medical University,
Ministry of Health of Russia; 8 Trubetskaya St., Build. 2, Moscow, 119991, Russia;
Russian Federation
Russian Federation
E. V. Konstantinova
Regional Vascular Center, N.I. Pirogov City Clinical Hospital One, Moscow Healthcare Department; 8 Leninsky Prospect, Build. 8, Moscow, 115149, Russia;
Acad. A.I. Nesterov Department of IntermediateLevel Therapy, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, 1 Ostrovityanov St., Moscow 117997, Russia
Russian Federation
Russian Federation
A. I. Trukhin
Regional Vascular Center, N.I. Pirogov City Clinical Hospital One, Moscow Healthcare Department; 8 Leninsky Prospect, Build. 8, Moscow, 115149, Russia;
Russian Federation
Russian Federation
References
1. Диагностика и лечение фибрилляции предсердий. Рекомендации ВНОК, ВНОА, АССХ (2012). http://scardio.ru/content/ Guidelines/FP_rkj_13. pdf. [Diagnostics and therapy of atrial fibrillation. Recommendations of All-Russian Scientific Society of Cardiologists, All-Russian Scientific Society of Arrhythmologists, Society of Cardiosurgeons (2012). URL: http://scardio.ru/content/ Guidelines/FP_rkj_13. pdf. (In Russ.)].
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm A.J. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC). Eur Heart J 2010;31(19):2369–429.
3. Camm A.J., Lip G., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719–47.
4. January C.T., Wann L.S., Alpert J.S. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014;130(23):2071–104.
5. Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillations: the Framingham Heart Study. Circulation 2004;110(9):1042–6.
6. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983–8.
7. Hart R.G., Pearce L.A., Rothbart R.M. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol 2000;35(1):183–7.
8. Hart R.G., Pearce L.A., Koudstaal P.J. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004;35(4):948–51.
9. Hohnloser S.H., Pajitnev D., Pogue J. et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50(22):2156–61.
10. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31(8):967–75.
11. Stoddard M.F., Dawkins P.R., Prince C.R., Ammash N.M. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: A transesophageal echocardiographic study. J Am Coll Cardiol 1995;25(2):452–9.
12. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61(2):755–9.
13. Wu N., Tong S., Xiang Y. et al. Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression. PLoS One 2015;10(4):e0124716.
14. Hart R.G., Pearce L.A., Aguilar M.I. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(1):857–67.
15. ACTIVE Investigators, Connolly S.J., Pogue J. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360(20):2066–78.
16. Cleland J.G., Cowburn P.J., Falk R.H. Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. Eur Heart J 1996;17(5):674–81.
17. Hylek E.M., Skates S.J., Sheehan M.A., Singer D.E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335(8):540–6.
18. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981–92.
19. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139–51.
20. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883–91.
21. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806–17.
22. Giugliano R.P., Ruff C.T., Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093–104.
23. Hughes M., Lip G.Y., Guideline Development Group et al. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Tromb Haemost 2008;99(2):295–304.
24. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69(6):546–54.
25. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National registry of atrial fibrillation. JAMA 2001;285(22):2864–70.
26. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263–72.
27. Pisters R., Lane D.A., Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey on atrial fibrillation. Chest 2010;138(5):1093–100.
28. Ebright J., Mousa S.A. Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Тhromb Hemost 2015;21(2):105–14.
29. Gomes T., Mamdani M.M., Holbrook A.M. et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ 2013;185(2):E121–7.
30. Hylek E.M., Evans-Molina C., Shea C. et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115(21):2689–96.
31. Camm J.A., Colombo A., Corbucci G., Padeletti L. Left atrial appendage closure: a new technique for clinical practice. Heart Rhythm 2014;11(3):514–21.
32. Давтян К.В., Ткачева О.Н., Калемберг А.А., Корецкий С.Н. Первый опыт имплантации окклюзирующих устройств в ушко левого предсердия с целью профилактики инсультов в Государственном научно-исследовательском центре профилактической медицины. Рациональная фармакотерапия в кардиологии 2014;10(3):307–11. [Davtyan K.V., Tkachyova O.N., Kalemberg A.A., Koretskiy S.N. First experience of implantation of occluding devices into the left atrial appendage to prevent strokes in the state research center of preventive medicine. Ratsionalnaya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology 2014;10(3):307–11. (In Russ.)].
33. Марцевич С.Ю., Воронина В.П., Дроздова Л.Ю. Здоровье и образование врача: две составляющие успеха. Рациональная фармакотерапия в кардиологии 2010;6(1):73–6. [Martsevich S.Y., Voronina V.P., Drozdova L.Y. Health and education of a doctor: Two components of success. Ratsionalnaya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology 2010;6(1):73–6. (In Russ.)].
34. Dorian P., Kongnakorn T., Phatak H. et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J 2014;35(28):1897–906.
35. Белоусов Ю.Б., Явелов И.С., Белоусов Д.Ю., Афанасьева Е.В. Анализ прямых затрат, ассоциированных с применением варфарина у пациентов с фибрилляцией предсердий. Рациональная фармакотерапия в кардиологии 2011;7(5):561–6. [Belousov Y.B., Yavelov I.S., Belousov D.Y., Afanasiyeva E.V. Analysis of direct costs associated with application of warfarin of patients with atrial fibrillation. Ratsionalnaya farmakoterapiya v kardiologii = Rational pharmacotherapy in cardiology 2011;7(5):561–6. (In Russ.)].
Review
For citations:
Gilyarov M.Yu., Konstantinova E.V., Trukhin A.I. CURRENT POSSIBILITIES OF ANTICOAGULANT THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION. The Clinician. 2015;9(3):15-21. (In Russ.) https://doi.org/10.17650/1818-8338-2015-9-3-15-21
Views:
1550
Email this article 